Kezar Life Sciences (KZR)
(Delayed Data from NSDQ)
$4.10 USD
+0.03 (0.74%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $4.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
KZR 4.10 +0.03(0.74%)
Will KZR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KZR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KZR
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
KZR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates
What Makes Kezar Life Sciences (KZR) a New Buy Stock
Other News for KZR
KZR: Kezar Life Sciences Maintains Neutral Rating by HC Wainwright & Co. | KZR Stock News
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial ...
Kezar Life Sciences (KZR) Seeks to Lift Hold on Zetomipzomib Trials | KZR Stock News
Kezar Life Sciences lifts partial clinical hold on PORTOLA Phase 2a trial
Kalamazoo Resources Updates Registered Office Address